# A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis

> **NCT03163966** · PHASE2 · COMPLETED · sponsor: **Rottapharm Biotech** · enrollment: 248 (actual)

## Conditions studied

- Rheumatoid Arthritis, DMARD-naive and Early Disease Patients

## Interventions

- **DRUG:** CR6086
- **DRUG:** Methotrexate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03163966
- **Lead sponsor:** Rottapharm Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-05
- **Primary completion:** 2019-01-08
- **Final completion:** 2019-01-08
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2021-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03163966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03163966, "A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03163966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*